Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
695.24M | 544.89M | 473.24M | 439.69M | 390.95M | Gross Profit |
93.76M | 67.04M | 58.59M | 45.74M | 54.89M | EBIT |
38.12M | 25.17M | 19.67M | 4.70M | 18.92M | EBITDA |
44.44M | 30.64M | 24.60M | 9.46M | 23.82M | Net Income Common Stockholders |
22.56M | 13.38M | 6.64M | 2.15M | 15.74M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
24.25M | 6.06M | 2.08M | 5.19M | 43.00K | Total Assets |
679.52M | 539.69M | 512.12M | 530.30M | 506.98M | Total Debt |
273.09M | 329.63M | 326.57M | 355.24M | 319.00M | Net Debt |
248.84M | 323.57M | 324.49M | 350.05M | 318.95M | Total Liabilities |
367.56M | 394.18M | 386.46M | 416.05M | 405.80M | Stockholders Equity |
293.28M | 140.34M | 121.01M | 110.20M | 96.58M |
Cash Flow | Free Cash Flow | |||
30.31M | 24.98M | -5.13M | -24.53M | 42.95M | Operating Cash Flow |
39.30M | 33.09M | 9.04M | -18.22M | 50.20M | Investing Cash Flow |
-70.68M | -30.22M | -24.24M | -20.12M | -41.62M | Financing Cash Flow |
49.57M | 1.11M | 12.08M | 43.49M | -8.95M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | $880.90M | 35.88 | 10.40% | ― | 27.59% | 61.97% | |
64 Neutral | $717.98M | 18.31 | 8.25% | ― | 2.65% | 3.34% | |
63 Neutral | $1.05B | 37.68 | 5.75% | 2.55% | 11.00% | 37.38% | |
52 Neutral | $1.15B | ― | -65.55% | ― | 3.95% | -5.53% | |
51 Neutral | $408.21M | ― | -17.38% | ― | 19.19% | ― | |
51 Neutral | $875.97M | ― | 42.49% | ― | 6.82% | 92.03% | |
48 Neutral | $6.46B | 1.17 | -48.25% | 2.67% | 19.50% | 0.61% |
The Pennant Group reported its financial results for the fiscal year and fourth quarter of 2024, highlighting a significant increase in revenue and net income compared to the previous year. The company achieved a total revenue of $695.2 million for the year, marking a 27.6% increase, and a net income of $22.6 million, a 68.6% rise over the prior year. The Home Health and Hospice Services segment saw substantial growth, with a 31.7% increase in revenue for the year. The company also provided guidance for 2025, anticipating continued growth with expected total revenue between $800 million and $865 million.